Medicine and HealthInternational Journal of Biological Sciences
Neddylation of HER2 Inhibits its Protein Degradation and promotes Breast Cancer Progression
X. Xia, T. Hu, et al.
This groundbreaking study reveals that HER2 neddylation regulates its expression and oncogenic activity, shedding light on a potential therapeutic target for breast cancer. Conducted by Xiaohong Xia and colleagues, the research uncovers how inhibiting neddylation enhances HER2 degradation and can synergize with trastuzumab to combat HER2-positive breast cancer.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
D. Candas-green, B. Xie, et al.
Medicine and Health
Open Access Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
Y. Harada, A. Sato, et al.
Health and Fitness
Urinary metabolomics signature of animal and plant protein intake and its association with 24-h blood pressure: the African-PREDICT study
M. Strauss-kruger, M. Pieters, et al.
Medicine and Health
Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
M. Lapin, K. H. Edland, et al.
